Advertisement


Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42

2016 San Antonio Breast Cancer Symposium

Advertisement

Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).



Related Videos

Breast Cancer

Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective

Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.

Breast Cancer

Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study

Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).

Breast Cancer
Symptom Management

Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease

Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).

Breast Cancer

Ruth O’Regan, MD, and Ann H. Partridge, MD, on HER2+ Breast Cancer: Results From the CLEOPATRA Trial

Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).

Advertisement

Advertisement




Advertisement